Clik here to view.
ViiV Healthcare to evaluate injectable HIV treatment
ViiV Healthcare, owned by GSK with Pfizer and Shionogi as shareholders, has started two Phase III studies designed to evaluate an investigational long-acting, injectable regimen of cabotegravir (ViiV...
View ArticleClik here to view.
Pfizer fined £85 million for 2600% drug price increase to NHS
The Competition and Markets Authority has imposed a record £84.2 million fine on the pharmaceutical manufacturer Pfizer, and a £5.2 million fine on the distributor Flynn Pharma after finding that each...
View ArticleClik here to view.
Pfizer’s breast cancer drug too expensive for NHS
The National Institute for Health and Care Excellence (NICE) has today published draft guidance which does not recommend breast cancer drug palbociclib (Ibrance, Pfizer) for routine funding on the NHS....
View ArticleClik here to view.
The Top 21…wealthiest pharma companies
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the...
View ArticleClik here to view.
Celltrion Healthcare & Pfizer’s biosimilar shows positive results in Crohn’s...
Celltrion Healthcare and Pfizer presented the primary outcome from its pivotal randomised controlled trial of CT-P13 (biosimilar of infliximab) in Crohn’s disease. The data indicate that the safety and...
View ArticleClik here to view.
Injectable drug delivery market worth US$624.50 billion by 2021
According to a new market research report published by MarketsandMarkets, the global injectable drug delivery market, in terms of value, is projected to reach US$624.50 Billion by 2021 from US$362.38...
View ArticleClik here to view.
2017 Pipelines: Drugs to watch
Eight new drugs will enter the market in 2017 and achieve blockbuster sales of >$900 billion by 2021, according to consensus sales forecast data from Clarivate Analytics Cortellis Competitive...
View ArticleClik here to view.
Pfizer’s Phase III study to treat hospital-acquired pneumonia a success
Positive results of Pfizer‘s REPROVE study showed that patients diagnosed with hospital-acquired pneumonia (HAP), treated with Zavicefta (ceftazidime-avibactam), a novel combination antibiotic for the...
View ArticleClik here to view.
Relocating the EMA: An open letter from EFPIA and Pharma Heads of Research
Our current system of medicines regulation offers an outstanding example of European cooperation at its finest. By joining forces across nation states, bringing together the best and brightest minds...
View ArticleClik here to view.
Sangamo and Pfizer to collaborate on Haemophilia A gene therapy
Sangamo Therapeutics and Pfizer have announced an exclusive, global collaboration and license agreement for the development and commercialisation of gene therapy programs for Haemophilia A, including...
View ArticleClik here to view.
Pfizer collaboration to reduce injectable contraceptive price
“New innovations in contraceptive technology are needed to expand the number of methods available to women and adolescents so they can take charge of their health and their futures.” Pfizer, the Bill...
View ArticleClik here to view.
ViiV Healthcare submits regulatory applications for HIV two-drug regimen
GSK and ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi Limited as shareholders, have announced regulatory submissions to the European Medicines...
View Article